Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Leukemia × capivasertib × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Breast Neoplasms 5 Melanoma 2 Disease Progression 2 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Lymphoma 1 Leukemia 1 Endometrial Neoplasms 1 Chondrosarcoma 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1

Interventions

venetoclax 17 Cyclophosphamide 13 Cytarabine 11 Azacitidine 6 fludarabine 5 revumenib 4 Dexamethasone 4 ruxolitinib 3 quizartinib 3 pirtobrutinib 3 blinatumomab 3 Trimethoprim, Sulfamethoxazole Drug Combination 3 Rituximab 3 Palliative Care 3 Granulocyte Colony-Stimulating Factor 3 Decitabine 3 Daunorubicin 3 Blood Specimen Collection 3 pembrolizumab 2 gamma-Globulins 2 fludarabine phosphate 2 aldesleukin 2 Watchful Waiting 2 Tacrolimus 2 Mycophenolic Acid 2 Interviews as Topic 2 Interleukin-2 2 Inotuzumab Ozogamicin 2 Immunotherapy, Adoptive 2 Immunoglobulins, Intravenous 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡